Daratumumab monotherapy has shown to significantly delay progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring. The results of the AQUILA study revealed that daratumumab reduced the risk for progression or death by 51% and had a low rate of treatment discontinuation due to toxicities. The study included 390 adults with high-risk smoldering multiple myeloma and showed improved progression-free survival, overall response rate, and overall survival in patients who received daratumumab. These findings suggest that daratumumab may be an effective treatment option for patients with high-risk smoldering multiple myeloma.
Source link
Daratumumab superior to active monitoring for high-risk smoldering multiple myeloma
